TICKERNERD
Menu
SERSERHealthcare · Biotechnology

SER Stock Forecast: Serina Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$2.87
+8.30% on the day

The 2 Wall Street analysts covering Serina Therapeutics, Inc. hold a median 12-month price target of $9.5 — +231.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 18 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$72.9M
Ticker Nerd rank
18 / 100
Median analyst target
$9.50
Analysts covering
2
Total return, dividends reinvested
1W
+2.5%
1M
+37.3%
YTD
+50.0%
1Y
−47.8%
From 52W high
−49.2%
From 52W low
+124.2%
$1.28
$5.65
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SER stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Serina Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
18 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
79
Revisions
68
Volatility
53
Accruals
43
Momentum
29
Value
24
Quality
14
Growth
8
Issuance
5

Size (79): Smaller than most of the companies we track.

Issuance (5): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SER stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SER, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26SERHigh $11.00Median $9.50Low $8.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $8.00Median $9.50High $11.00

The green dot is the last close — the median target sits +231.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
1 July 2026BTIGInitiatesBuy—
28 Aug 2025HC Wainwright & Co.ReiteratesBuy—
14 July 2025HC Wainwright & Co.InitiatesBuy—
11 Mar 2025Jones TradingInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SER appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

SER analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Serina Therapeutics, Inc. (SER) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
1.6×

Cheaper than 70% of US stocks

Price / sales
328.8×

Cheaper than 3% of US stocks

Price / book
3.4×

Cheaper than 31% of US stocks

EV / EBITDA
−2.1×

Cheaper than 71% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−207.9%

Higher than 7% of US stocks

Return on assets
−92.3%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

SER vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SERSerina Therapeutics, Inc.$72.9M
18
PLRXPliant Therapeutics, Inc.$71.5M
66
LONALeonaBio, Inc.$71.5M
44
IBIOiBio, Inc.$71.0M
26
OSTXOS Therapies, Inc.$70.8M
29
PMVPPMV Pharmaceuticals, Inc.$70.5M
68
GOSSGossamer Bio, Inc.$75.6M
54

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Serina Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SER news & analysis

Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

GlobeNewsWire · 13 Aug 2026neutral

Serina Therapeutics reported its financial results for the second quarter ended June 30, 2026, and provided key business updates. The company is a clinical-stage biotechnology firm focused on its POZ Platform drug optimization technology.

Why it matters — The quarterly financial results and business updates offer a regular check on Serina's financial health and progress with its POZ Platform technology.

Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

GlobeNewsWire · 24 July 2026neutral

Serina Therapeutics announced that management will participate in the BTIG Virtual Biotechnology Conference, taking place July 28-29, 2026.

Why it matters — Conference participation gives Serina an opportunity to present its POZ Platform drug optimization technology to the investment community.

FAQ

Frequently asked questions about SER stock

What is the SER stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Serina Therapeutics, Inc. have a median 12-month price target of $9.5, with estimates ranging from $8 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SER stock a buy right now?

Of the 2 analysts covering Serina Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Serina Therapeutics, Inc. 18 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SER?

As at 22 Aug 2026, Serina Therapeutics, Inc. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (79 of 100).

Will SER stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +231.0% from the last close, and Ticker Nerd's factor model ranks Serina Therapeutics, Inc. 18 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SER stock forecast for 2030?

No analyst covering Serina Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SER are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $11 over the next 12 months.

How has SER stock performed over the past year?

Serina Therapeutics, Inc. returned -47.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Serina Therapeutics, Inc. do?

Serina Therapeutics Inc., a biopharmaceutical company, focuses on the development of polymer-based therapeutics to address significant medical challenges. The company's primary innovation lies in its proprietary polyoxazoline (POZ) polymer technology, which is engineered to enhance the delivery and efficacy of pharmaceuticals.

What is the latest news on SER?

The most recent item we track (GlobeNewsWire, 13 Aug 2026): "Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates". Serina Therapeutics reported its financial results for the second quarter ended June 30, 2026, and provided key business updates. The company is a clinical-stage biotechnology firm focused on its POZ Platform drug optimization technology.

Company

About Serina Therapeutics, Inc.

Serina Therapeutics Inc., a biopharmaceutical company, focuses on the development of polymer-based therapeutics to address significant medical challenges. The company's primary innovation lies in its proprietary polyoxazoline (POZ) polymer technology, which is engineered to enhance the delivery and efficacy of pharmaceuticals. This novel platform aims to improve the pharmacokinetics and safety profiles of their drug candidates, making it a promising solution for patients with unmet medical needs. Serina Therapeutics operates within the biotechnology and pharmaceutical sectors, emphasizing the treatment of neurological diseases, cancer, and autoimmune conditions. The company's POZ technology has the potential to impact the drug delivery landscape, offering tailored solutions that prolong the drug's duration in the system and minimize side effects, thereby increasing therapeutic efficacy. In the competitive landscape of biopharmaceutical innovation, Serina Therapeutics Inc. plays a vital role by advancing the development of next-generation therapeutics that align with the evolving demands of precision medicine.

CEO Mr. Steven A. Ledger · 16 employees · United States · https://serinatherapeutics.com